SELECTIVE OXIDATION OF O-XYLENE TO PHTHALIC-ANHYDRIDE OVER THE EUROCAT V2O5/TIO2 CATALYSTS

The selective oxidation of o-xylene to phthalic anhydride has been studied in four laboratories, using catalysts EL10V1 and EL10V8; conversions and product yields as a function of time-on-stream are reported. The results obtained are in generally good agreement: for both catalysts, phthalic anhydride yields at 40% conversion are ca. 20%, rising to 63-70% at 100% conversion. Increasing the vanadium content from 1 to 8% has little effect and may even result in a slightly worse performance. Differences in the temperatures required to attain a fixed conversion may reflect differences in reactor design, especially with regard to heat exchange efficiency

Oekologischer Waldumbau und naturschutzbezogene Waldforschung im Nordostdeutschen Tiefland. TP2: Auswirkungen des Waldumbaus auf naturschutz- und waldschutzrelevante Arthropoden im Nordostdeutschen Tiefland Schlussbericht

SIGLEAvailable from TIB Hannover: F04B277 / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekBundesministerium fuer Bildung und Forschung (BMBF), Bonn (Germany)DEGerman

Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast Cancer

BACKGROUND: We evaluated both estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status on disseminated tumor cells (DTCs) in the bone marrow of 54 patients with early breast cancer and compared these with the corresponding primary tumor (PT). MATERIALS AND METHODS: Bone marrow aspirates were obtained at the time of first surgery, and ER and HER2 status on DTCs was assessed simultaneously by immunocytochemistry using a triple fluorescence staining method. RESULTS: The median number of DTCs was 13 (range 1-95). The concordance rate between ER status on DTC and PT was 74%. Patients with an ER-positive PT were significantly more likely to have at least one ER-positive DTC (34 out of 42) than patients with an ER-negative PT (6 out of 12; P = .031). Thirty-nine (93%) of the 42 patients with ER-positive PT had at least one ER-negative DTC. The concordance rate between HER2 status on DTC and PT was 52%. The probability of having at least one HER2-positive DTC was not related to the HER2 status of the PT (P = 0.56). Twenty-two (46%) of the 48 patients with a HER2-negative PT had at least one HER2-positive DTC. All the six patients with a HER2-positive PT had at least one HER2-negative DTC. CONCLUSION: Taken together, our study confirms that ER and/or HER2 status may differ between DTC and PT. This discordance could be important for patients lacking ER or HER2 expression on the PT but showing ER-positive or HER2-positive DTC because they might benefit from an endocrine and/or HER2-targeted therapy